Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 ⁎ 28 Mutation

Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 ⁎ 28 Mutation

Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary macroadenoma who underwent transsphenoidal surgery....

Full description

Bibliographic Details
Main Authors:	Maria Susana Mallea-Gil, Ignacio Bernabeu, Adriana Spiraquis, Alejandra Avangina, Lourdes Loidi, Carolina Ballarino
Format:	Article
Language:	English
Published:	Hindawi Limited 2016-01-01
Series:	Case Reports in Endocrinology
Online Access:	http://dx.doi.org/10.1155/2016/2087102

Similar Items

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report
by: A. Ciresi, et al.
Published: (2018-01-01)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
by: Natalia Ximena Garcia Basavilbaso, et al.

Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
by: Radhian Amandito, et al.
Published: (2019-08-01)

Commentary: Profiling of UGT1A1*6, UGT1A1*60, UGT1A1*93, and UGT1A1*28 Polymorphisms in Indonesian Neonates With Hyperbilirubinemia Using Multiplex PCR Sequencing
by: Mohammad Reza Heydari, et al.
Published: (2020-02-01)

Pegvisomant for acromegaly: does it always works?
by: Sebastian J. Neggers, et al.

Acromegalic gigantism
by: Geddes, A. C.
Published: (1908)

Detection of UGT1A1*28 Polymorphism Using Fragment Analysis
by: Ying HUANG, et al.
Published: (2017-12-01)

Brazilian multicenter study on pegvisomant treatment in acromegaly
by: Cesar L. Boguszewski, et al.

Pseudoacromegaly with acromegalic features in radiography
by: Koichiro Yamamoto, et al.
Published: (2021-05-01)

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
by: Panagopoulos P, et al.
Published: (2017-06-01)

Unusual AIP mutation and phenocopy in the family of a young patient with acromegalic gigantism
by: Syed Ali Imran, et al.
Published: (2018-01-01)

Lipodystrophy during pegvisomant therapy: a case report and review of the literature
by: D Buyuktas, et al.
Published: (2010-01-01)

Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28
by: Tian C, et al.
Published: (2018-11-01)

Significance of UGT1A1*28 genotype in patients with advanced liver injury caused by chronic hepatitis C
by: Jordović Jelena, et al.
Published: (2019-01-01)

Hyperbilirubinemia in atazanavir-treated human immunodeficiency virus-infected patients: the impact of the UGT1A1*28 allele
by: Naidoo A, et al.
Published: (2017-08-01)

Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy
by: Bai Y, et al.
Published: (2017-06-01)

Characterization of mutation UGT1A4 in Taiwan colorectal cancer patients
by: LIN, YI-CHIUN, et al.
Published: (2009)

Pegvisomant and current approaches to the medical treatment of acromegaly (literature review and case report)
by: Larisa K. Dzeranova, et al.
Published: (2020-03-01)

Perioperative consideration of general anesthesia for acromegalic patients
by: Seunghyun Kang, et al.
Published: (2014-12-01)

Handia (2017). Life of an acromegalic in XIX century
by: Emilio PINTOR HOLGUÍN, et al.
Published: (2018-12-01)

The Evaluation of Genetic Profiles of UGT1A4 and UGT1A6 in the Turkish Population
by: Zuhal Uçkun Şahinoğulları
Published: (2021-03-01)

The efficacy and safety of direct-acting antiviral agents in patients with chronic HCV infection and UGT1A1*28 polymorphism
by: Lukashyk S.P., et al.
Published: (2020-03-01)

Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer.
by: Solen Pichereau, et al.
Published: (2011-01-01)

Epigenetics and microRNAs in UGT1As
by: Cui-Lan Meng, et al.
Published: (2021-05-01)

The polymorphisms of UGT1A7 and UGT1A10 among Taiwan lung cancer patients.
by: LEE, YU-CHING, et al.
Published: (2005)

UGT1A1 Gene Mutation due to Crigler-Najjar Syndrome in Iranian Patients: Identification of a Novel Mutation
by: Javad Mohammadi Asl, et al.
Published: (2013-01-01)

Mitochondrial Mutations in Cholestatic Liver Disease with Biliary Atresia
by: Hong Koh, et al.
Published: (2018-01-01)

Drug serum levels and genetic polymorphisms of UGT1A3, UGT1A4, UGT2B7 and HLA involved in lamotrigine hypersensitivity.
by: Chun-Yi Wu, et al.
Published: (2010)

Body fat percentage is a major determinant of total bilirubin independently of UGT1A1*28 polymorphism in young obese.
by: Luís Belo, et al.
Published: (2014-01-01)

A rare complication: Infection in acromegalic renal cysts
by: Yuki Mori, et al.
Published: (2020-12-01)

Good Outcome Following Copeland Hemiarthroplasty for Acromegalic Arthropathy
by: S. E. Johnson-Lynn, et al.
Published: (2011-01-01)

The pathogenesis of octreotide-associated gallbladder stones in acromegalic patients
by: Hussain, Syed Hyder
Published: (1996)

Prevalence and recurrence rate of colonic lesions in acromegalic patients
by: Berker Dilek, et al.
Published: (2010-12-01)

Glucose and Lipid Abnormalities in Newly Diagnosed Acromegalic Patients
by: Vlad Mihaela, et al.
Published: (2015-03-01)

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
by: Alicia Romero-Lorca, et al.
Published: (2015-01-01)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
by: Lingyun Ma, et al.
Published: (2020-08-01)

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
by: Connock Martin J, et al.
Published: (2009-10-01)

Correction: Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.
by: PLOS ONE Staff
Published: (2015-01-01)

Genetic Polymorphism of UGT1A1 Gene in Chinese
by: Liu, Chin Hung, et al.
Published: (1999)

A novel UGT1A1 gene mutation causing severe unconjugated hyperbilirubinemia: a case report
by: Xiaoxia Shi, et al.
Published: (2019-05-01)

Cannot write session to /tmp/vufind_sessions/sess_elgj7snqi7kd8ib2d1b2dg9i0t